<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:department>Division of Genetics and Epidemiology</gtr:department><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/81DB41BF-4408-4773-9D7F-D44B62812066"><gtr:id>81DB41BF-4408-4773-9D7F-D44B62812066</gtr:id><gtr:firstName>Nazneen</gtr:firstName><gtr:surname>Rahman</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0400188"><gtr:id>109FCC2C-3118-4C6D-9BAF-7088049E4C55</gtr:id><gtr:title>The Genetics of Human Overgrowth Conditions</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400188</gtr:grantReference><gtr:abstractText>In addition to publication in peer reviewed journals we will submit any new data for presentation at appropriate meetings. Diagnostic and management guidelines will be published and potentially may be made more freely available, if ratified by the Clinical Genetics Society, on their website and/or as a leaflet. We have strong contacts with the Child Growth Foundation and the Sotos syndrome society who provide information and support to families with growth disorders and would make clinically relevant research findings available to them to disseminate to families. The Institute s press office reviews all research projects and where appropriate, and in consultation with the relevant funding body, the press office will communicate with the public through the media.</gtr:abstractText><gtr:technicalSummary>An overgrowth syndrome is a condition in which there is generalised or localised areas of excess growth compared either to another part of the body, or to other children of similar age. Many different medical problems can be associated with overgrowth including learning difficulties, heart defects and cancer. Overgrowth syndromes include a large number of diverse conditions whose classification, diagnosis, management and complex molecular causes are poorly understood. Furthermore, many children do not fit into any of the currently recognised syndromes. The proposed research aims to investigate the molecular causes of overgrowth syndromes using samples and clinical data collected by the Childhood Overgrowth Consortium from hundreds of overgrowth cases. We will review the data from these cases to define the clinical spectrum of overgrowth syndromes and the nature and frequency of associated medical problems. We will use a combination of strategies to try to identify the underlying molecular causes of overgrowth conditions. This will include investigation of familial overgrowth cases for linkage to specific genes, investigation of cases with chromosome abnormalities to identify which genes are altered by the chromosomal defect, and high-throughput screening of candidate genes for mutations that may lead to overgrowth. We will also use microarray technology to look for submicroscopic chromosome alterations that may cause overgrowth conditions and to look for changes in the expression of genes that may be characteristic for different overgrowth conditions. 
The research will have clinical relevance and should result in evidence-based guidelines for the diagnosis and management of overgrowth conditions as well as information for families about the risk to other family members. The research will also provide insights into fundamental mechanisms of growth control, in particular the processes that control our overall size and the mechanisms by which this can be subverted. These insights may increase our understanding of normal developmental biology and other diseases in which there is loss of growth control, such as cancer.</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>527559</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Institute of Child Health</gtr:department><gtr:description>Lead of Childhood Overgrowth Collaboration</gtr:description><gtr:id>15EF1474-4653-49E9-88F1-9DAF3FB5E277</gtr:id><gtr:impact>All the publications underpinned by this programme have resulted from this collaboration</gtr:impact><gtr:partnerContribution>The collaboration has provided samples and mutational data and intellectual inputsamples

NB there are many others - which are acknowledged in my papers but I cannot fill them all in here</gtr:partnerContribution><gtr:piContribution>I lead the international Childhood overgrowth collaboration which includes many 100s of collaborators across the world. My research coordinates and largely undertakes the experimental work of the collaboration</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Birmingham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Lead of Childhood Overgrowth Collaboration</gtr:description><gtr:id>0BF56540-00C6-4D9A-81A2-BC1D1B03832B</gtr:id><gtr:impact>All the publications underpinned by this programme have resulted from this collaboration</gtr:impact><gtr:partnerContribution>The collaboration has provided samples and mutational data and intellectual inputsamples

NB there are many others - which are acknowledged in my papers but I cannot fill them all in here</gtr:partnerContribution><gtr:piContribution>I lead the international Childhood overgrowth collaboration which includes many 100s of collaborators across the world. My research coordinates and largely undertakes the experimental work of the collaboration</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Dissemination to patients</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8792CE1D-8602-41F6-8C76-3C82DEC2AF1E</gtr:id><gtr:impact>Increased understanding for participants. Direct clinical benefit

Direct clinical benefit for families</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR/BRC</gtr:department><gtr:description>Senior Investigator award</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>B3C1C2B6-0EF1-49E4-8C38-6EB2679E1D63</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research project</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Child Growth Foundation</gtr:fundingOrg><gtr:id>11CF886F-6D92-4710-B865-E13D2C79D5EE</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2183000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Senior Investigator Award</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>100210/2/12/2</gtr:fundingRef><gtr:id>29394E9B-6547-4489-BA2A-160E8F8952B1</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Protocol for management of NSD1 gene mutations</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>677F6224-DBE9-4289-B596-56F6CD0BB175</gtr:id><gtr:impact>We defined the clinical presentation and molecular defects of a condition known as Sotos syndrome which is caused by NSD1 mutations. Our papers and presentations are recognised as the gold standard and our management protocols are used broadly by clinicians internationally.</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/books/NBK1479/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in multiple clinical review</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>1D25451A-F8E7-4542-846D-10A8F48AE5B2</gtr:id><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Global Alliance for Genomics and Health</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>DA0AA165-1E9B-4C6C-AB5C-2B01AC6D1E45</gtr:id><gtr:type>Membership of a guideline committee</gtr:type><gtr:url>https://genomicsandhealth.org/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Development of diagnostic assays</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>3EDC1739-9998-4007-89DE-51EF1DCC7859</gtr:id><gtr:impact>We developed diagnostic tests for NSD1 and for epigenetic defects at 11p15. These are used in the NHS in UK and we also assisted labs elsewhere in the world to develop assays and in providing positive controls.</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have made cell lines from samples with unique mutations and phenotypes which we have made available to other researchers and deposited in cell line repositories</gtr:description><gtr:id>F482EA73-C757-412E-9454-1EC24FC8E140</gtr:id><gtr:impact>Publications utilising our cell lines have been published e.g. 84. Berdasco M, Ropero S, Setien F, Fraga MF, Lapunzina P, Losson R, Alaminos M, Cheung NK, Rahman N and Esteller M. (2009) Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc Natl Acad Sci USA. 106: 21830-21835</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>cell lines from overgrowth patients</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6C44E36B-61A9-4723-B00D-08343B394F18"><gtr:id>6C44E36B-61A9-4723-B00D-08343B394F18</gtr:id><gtr:title>Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6868686543ba7ea4e97f69f172a3ecd0"><gtr:id>6868686543ba7ea4e97f69f172a3ecd0</gtr:id><gtr:otherNames>Tatton-Brown K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E1E82FBB-4DBA-40BC-96F8-86D1C1045AEF"><gtr:id>E1E82FBB-4DBA-40BC-96F8-86D1C1045AEF</gtr:id><gtr:title>Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2b43f8748ad83cbb9c9dccfee3890f5e"><gtr:id>2b43f8748ad83cbb9c9dccfee3890f5e</gtr:id><gtr:otherNames>Scott RH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/797D0820-9F0B-4342-877A-9A5D294D2AEB"><gtr:id>797D0820-9F0B-4342-877A-9A5D294D2AEB</gtr:id><gtr:title>Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6868686543ba7ea4e97f69f172a3ecd0"><gtr:id>6868686543ba7ea4e97f69f172a3ecd0</gtr:id><gtr:otherNames>Tatton-Brown K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3C93ADD0-BEAF-48E3-B497-92CFF1999C85"><gtr:id>3C93ADD0-BEAF-48E3-B497-92CFF1999C85</gtr:id><gtr:title>Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6868686543ba7ea4e97f69f172a3ecd0"><gtr:id>6868686543ba7ea4e97f69f172a3ecd0</gtr:id><gtr:otherNames>Tatton-Brown K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/80A4CF5C-7878-4479-A60B-2BCCE3F535D5"><gtr:id>80A4CF5C-7878-4479-A60B-2BCCE3F535D5</gtr:id><gtr:title>Facial dysmorphism and digit anomalies in three siblings with severe developmental delay.</gtr:title><gtr:parentPublicationTitle>Clinical dysmorphology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d7b6e0979d3658f608bbf701beb0ba71"><gtr:id>d7b6e0979d3658f608bbf701beb0ba71</gtr:id><gtr:otherNames>Mueller JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0962-8827</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/22E9F9AD-F48B-4B1E-BF16-D25D25CEED84"><gtr:id>22E9F9AD-F48B-4B1E-BF16-D25D25CEED84</gtr:id><gtr:title>Multiple mechanisms are implicated in the generation of 5q35 microdeletions in Sotos syndrome.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6868686543ba7ea4e97f69f172a3ecd0"><gtr:id>6868686543ba7ea4e97f69f172a3ecd0</gtr:id><gtr:otherNames>Tatton-Brown K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/353DB636-F8B8-4BC1-996C-20A1AC298579"><gtr:id>353DB636-F8B8-4BC1-996C-20A1AC298579</gtr:id><gtr:title>Weaver syndrome and EZH2 mutations: Clarifying the clinical phenotype.</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6868686543ba7ea4e97f69f172a3ecd0"><gtr:id>6868686543ba7ea4e97f69f172a3ecd0</gtr:id><gtr:otherNames>Tatton-Brown K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1552-4825</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D1030EF8-C09F-4BD6-861B-F9A248A82DCC"><gtr:id>D1030EF8-C09F-4BD6-861B-F9A248A82DCC</gtr:id><gtr:title>Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6868686543ba7ea4e97f69f172a3ecd0"><gtr:id>6868686543ba7ea4e97f69f172a3ecd0</gtr:id><gtr:otherNames>Tatton-Brown K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E9DA5257-8F5C-4371-9231-FB89829E7937"><gtr:id>E9DA5257-8F5C-4371-9231-FB89829E7937</gtr:id><gtr:title>Mutations in RNF135, a gene within the NF1 microdeletion region, cause phenotypic abnormalities including overgrowth.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0158dcd54c77c32c28d389fa2f0c6020"><gtr:id>0158dcd54c77c32c28d389fa2f0c6020</gtr:id><gtr:otherNames>Douglas J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/543F6094-138D-403B-B52C-F05F3CB9544A"><gtr:id>543F6094-138D-403B-B52C-F05F3CB9544A</gtr:id><gtr:title>Mutations in the PP2A regulatory subunit B family genes PPP2R5B, PPP2R5C and PPP2R5D cause human overgrowth.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e36ab8ab4113e4d22efa24b7e54ff6ee"><gtr:id>e36ab8ab4113e4d22efa24b7e54ff6ee</gtr:id><gtr:otherNames>Loveday C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9BBF5687-930E-444D-8846-176C0EE1E0E4"><gtr:id>9BBF5687-930E-444D-8846-176C0EE1E0E4</gtr:id><gtr:title>Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) robustly detects and distinguishes 11p15 abnormalities associated with overgrowth and growth retardation.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2b43f8748ad83cbb9c9dccfee3890f5e"><gtr:id>2b43f8748ad83cbb9c9dccfee3890f5e</gtr:id><gtr:otherNames>Scott RH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7486D45C-E0C6-4A6D-B4E6-A1CB54542D4A"><gtr:id>7486D45C-E0C6-4A6D-B4E6-A1CB54542D4A</gtr:id><gtr:title>15q overgrowth syndrome: a newly recognized phenotype associated with overgrowth, learning difficulties, characteristic facial appearance, renal anomalies and increased dosage of distal chromosome 15q.</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6868686543ba7ea4e97f69f172a3ecd0"><gtr:id>6868686543ba7ea4e97f69f172a3ecd0</gtr:id><gtr:otherNames>Tatton-Brown K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1552-4825</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B681D803-B226-4E41-AE1F-57BF68CBA50E"><gtr:id>B681D803-B226-4E41-AE1F-57BF68CBA50E</gtr:id><gtr:title>Partial NSD1 deletions cause 5% of Sotos syndrome and are readily identifiable by multiplex ligation dependent probe amplification.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0158dcd54c77c32c28d389fa2f0c6020"><gtr:id>0158dcd54c77c32c28d389fa2f0c6020</gtr:id><gtr:otherNames>Douglas J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/03A29F3F-4690-4188-BFCF-9909641285B6"><gtr:id>03A29F3F-4690-4188-BFCF-9909641285B6</gtr:id><gtr:title>Familial gigantism caused by an NSD1 mutation.</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aa1bce9659830261f2322681765ee483"><gtr:id>aa1bce9659830261f2322681765ee483</gtr:id><gtr:otherNames>van Haelst MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1552-4825</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C0F25BBB-A6AC-4A42-ADFA-312E2028E6E0"><gtr:id>C0F25BBB-A6AC-4A42-ADFA-312E2028E6E0</gtr:id><gtr:title>Mechanisms predisposing to childhood overgrowth and cancer.</gtr:title><gtr:parentPublicationTitle>Current opinion in genetics &amp; development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e7c2c20e322a1b7a7e238e13e86adfdc"><gtr:id>e7c2c20e322a1b7a7e238e13e86adfdc</gtr:id><gtr:otherNames>Rahman N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0959-437X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0C47633D-91CF-45DA-B96C-C3B7D159D122"><gtr:id>0C47633D-91CF-45DA-B96C-C3B7D159D122</gtr:id><gtr:title>Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/be5d036f68cbae1662edcfcddc9394e6"><gtr:id>be5d036f68cbae1662edcfcddc9394e6</gtr:id><gtr:otherNames>Berdasco M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/34E06166-0B10-4B83-9F13-F847D8823378"><gtr:id>34E06166-0B10-4B83-9F13-F847D8823378</gtr:id><gtr:title>The NSD1 and EZH2 overgrowth genes, similarities and differences.</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part C, Seminars in medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6868686543ba7ea4e97f69f172a3ecd0"><gtr:id>6868686543ba7ea4e97f69f172a3ecd0</gtr:id><gtr:otherNames>Tatton-Brown K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1552-4868</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7E5354A7-7171-420E-9437-A07DF1484ACE"><gtr:id>7E5354A7-7171-420E-9437-A07DF1484ACE</gtr:id><gtr:title>Sotos syndrome.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6868686543ba7ea4e97f69f172a3ecd0"><gtr:id>6868686543ba7ea4e97f69f172a3ecd0</gtr:id><gtr:otherNames>Tatton-Brown K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9089B60F-D4C2-440A-A8B8-08215E1AF24E"><gtr:id>9089B60F-D4C2-440A-A8B8-08215E1AF24E</gtr:id><gtr:title>Mutations in Epigenetic Regulation Genes Are a Major Cause of Overgrowth with Intellectual Disability.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6868686543ba7ea4e97f69f172a3ecd0"><gtr:id>6868686543ba7ea4e97f69f172a3ecd0</gtr:id><gtr:otherNames>Tatton-Brown K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400188</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>78FE8F42-8AFB-48F8-8662-37D541AD95BF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Congenital Disorders</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>